Stock Mumak

Stock Profile

Eli Lilly

Eli Lilly is one of the leading pharmaceutical companies worldwide. Growth drivers include Mounjaro, Zepbound, and a strong pipeline in obesity, diabetes, oncology, and neuroscience.

Stock Snapshot

Eli Lilly_Logo
Table HeaderTable Header
CompanyEli Lilly and Company
SectorHealthcare
ThemePharmaceuticals & Biotechnology
Business ModelDevelopment and commercialization of innovative medicines focusing on diabetes, obesity, and oncology
ISINUS5324571083
Market Capitalizationapprox. USD 1 trillion
UMBRELLA StatusActive
  • Geopolitics
  • Industry
  • Fundamentals
  • Sentiment
  • Technical Analysis

Price Performance (12 Months)

Aktuelle Unternehmensmeldungen

Eli Lilly
Healthcare

Valuation Analysis: Eli Lilly and Company

ISIN: US5324571083

Eli Lilly delivered strong revenue and earnings growth in the second quarter of 2026. Mounjaro and Zepbound are driving the business, revenue guidance is rising, and market sentiment is improving. At the same time, the high valuation, falling net prices in the US, heavy investment, and weak free cash flow remain key risks.
Compass 4 out of 5
Active icon
More research

Latest Portfolio Updates

Weekly Update

Weekly Market Overview – September 14-September 20, 2026

UMBRELLA Strategy: Technology weighting expanded following portfolio adjustments.
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Intel becomes part of the UMBRELLA Strategy

Intel was newly added to the UMBRELLA Strategy, expanding the portfolio's semiconductor positioning. At the same time, Revolution Medicines, Bayer,
Next Update
RED HOT CHILI™ MUMAK

RED HOT CHILI™ MUMAK of the Week: No Award This Week

The RED HOT CHILI™ MUMAK will not be awarded this week.
Next Update
Revolution Medicines
Company Update

Revolution Medicines Update: FDA Breakthrough Therapy designation expands RASONQUE’s potential

Revolution Medicines receives another FDA Breakthrough Therapy designation for RASONQUE.
Next Update